Please use this identifier to cite or link to this item: http://dl.umsu.ac.ir/handle/1805/2737
Title: Neurexophilin1 suppresses the proliferation of hematopoietic progenitor cells
Authors: Broxmeyer, Hal E.;Pelus, Louis;Harrington, Maureen A.;Nakshatri, Harikrishna;Kinzfogl, John M
subject: Neurexin I alpha;Neurexophilin;Dystroglycan;Hematopoiesis;Hematopoietic niche;Hematopoiesis;Hematopoietic stem cells;Proteins
Year: 16-Mar-2012
Description: Indiana University-Purdue University Indianapolis (IUPUI)
Neurexin I alpha (NRXN1α) and Dystroglycan (DAG1) are membrane receptors which serve as mutual ligands in the neuronal system. Neurexophilins (NXPHs) bind NRXN1α. Both NRXN1α and DAG1 were expressed in primitive populations in human cord blood (huCB) and murine bone marrow (muBM), with high concentrations of NXPHs in huCB plasma. We evaluated effects of these molecules on huCB and muBM hematopoietic progenitor (HPC) and stem (HSC) cells. At both a single and population level in vitro, we found that NXPH1 is a potent inhibitor of HPC proliferation acting through NRXN1α, an effect antagonized by DAG1. Injection of recombinant NXPH1 in vivo resulted in myelo- and lymphosuppression, with absolute numbers and cycling status of functional and phenotypically defined HPCs dose- and time-dependently decreased, and absolute numbers and cycling status of phenotypically defined longer-term repopulation HSCs increased. Competitive transplants showed an initial decrease in engraftment of NXPH1-treated cells, with an intermediate stage increase in engraftment. The increase in HSCs is at least partially mediated by the mTOR pathway and is thought to be homeostatic in nature. These results demonstrate the presence and function of a regulated signaling axis in hematopoiesis centered on NRXN1α and its modulation by DAG1 and NXPH1.
URI: http://hdl.handle.net/1805/2737
Appears in Collections:Theses, Dissertations, and Doctoral Papers

Files in This Item:
Click on the URI links for accessing contents.


Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.